来自官方财务报表的收入、利润与现金流历史。
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹91.2B | ₹78.1B | ₹65.8B | ₹59.3B | — |
| 毛利 | ₹52.2B | ₹44.9B | ₹39.7B | ₹35.2B | — |
| 营业利润（EBIT） | ₹13.7B | ₹10.8B | ₹9.2B | ₹9.4B | — |
| 净利 | ₹9.2B | ₹6.8B | ₹5.0B | ₹5.3B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 EMCURE 交互式查看器。 /companies/us/EMCURE
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms